Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
16 results
D1.313 - Clinical Characteristics of Chronic Urticaria Patients With and Without Flares With Systemic Symptoms
D1.315 - IgE antibody function and mast cell activation to egg in children undergoing baked and loosely cooked egg challenges
D1.304 - Exercise-induced anaphylaxis misdiagnosed as cholinergic urticaria in a child: a case report
D1.308 - Severe Chronic Spontaneous Urticaria with Recurrent Anaphylaxis and Extreme IgE Elevation Associated with Innate Immune Dysregulation
D1.309 - The complexity of basal serum tryptase levels: Genotyping tryptase genes is not enough
D1.314 - Endothelial glycocalyx shedding in IgE- and IgG-mediated anaphylaxis
D1.316 - Identification of lipid classes to differentiate anaphylactic from non-anaphylactic allergic reactions. BANA study
D1.320 - IgE-mediated Perioperative Anaphylaxis to Latex with Concomitant Local Anesthetic Hypersensitivity in a Mexican Teenager: a Policy-Changing Case Report
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child
D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD
D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis
Download the app
The congress at your fingertips
Available on
Download